Rid­ing on wave of clin­i­cal tri­al re­forms, ma­chine learn­ing start­up bags $50M to cre­ate 'dig­i­tal twin­s'

As drug de­vel­op­ers and reg­u­la­tors alike in­creas­ing­ly warm to cre­ative ideas for run­ning clin­i­cal tri­als, a ma­chine learn­ing plat­form cre­at­ed by three physi­cists is draw­ing in $50 mil­lion from tech VCs.

Un­learn bills it­self as the on­ly com­pa­ny that can gen­er­ate “dig­i­tal twins” of pa­tients for use in clin­i­cal tri­als, so that bio­phar­ma com­pa­nies can test their drugs with few­er re­al pa­tients than they would need to in tra­di­tion­al tri­als, but get sim­i­lar­ly, if not even more, re­li­able re­sults.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER